Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial

BACKGROUND: Durvalumab after concurrent chemoradiotherapy (cCRT) is the standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). However, patients often receive sequential chemoradiotherapy (sCRT) due to factors including advanced age or frailty, comorbidities, or disease- or access-related concerns. The phase II PACIFIC-6 trial (NCT03693300) evaluated the safety of durvalumab after sCRT in this setting. Interim results indicated a similar safety profile to that observed with durvalumab after cCRT, with encouraging preliminary efficacy. We report outcomes from the final analysis. PATIENTS AND METHODS: Adults with unresectable, stage III NSCLC, Eastern Cooperative Oncology Group performance status

• Garassino, M. C.
• Khalifa, J.
• Reck, M.
• Chouaid, C.
• Bischoff, H.
• Reinmuth, N.
• Cove-Smith, L.
• Mansy, T.
• Cortinovis, D. L.
• Migliorino, M. R.
• Delmonte, A.
• Garcia Sánchez, J.
• Chara Velarde, L. E.
• Bernabe, R.
• Paz-Ares, L.
• Chander, P.
• Diaz Perez, I.
• Foroutanpour, K.
• Emeribe, U.
• Faivre-Finn, C.